Le notizie dalla Borsa Italiana del adc-therapeutics-announces-initial-results-from-investigator-initiated-phase-2-clinical-trial-evaluating-zynlonta-in-combination-with-rituximab-in-patients-with-relapsed-refractory-follicular-lymphoma-fl-1747658


Condividi